The Vox Markets Podcast / Jeremy Skillington of Poolbeg Pharma discusses their exclusive in-licence of RNA-based immunotherapy asset

Our new player has been redesigned to fit in better wherever you embed it. Feedback is welcome on our support site.
You can still use our old player if you prefer.